Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 68
Filter
Add more filters

Complementary Medicines
Country/Region as subject
Publication year range
1.
Toxicol Appl Pharmacol ; 427: 115650, 2021 09 15.
Article in English | MEDLINE | ID: mdl-34273408

ABSTRACT

Most research on medical countermeasures for nerve agent exposure assumes a military scenario, in which (autoinjector) treatment is envisaged to be available immediately. In a civilian setting however, treatment is delayed until arrival of first-aid responders. This may significantly affect treatment efficacy and the requirements for secondary intensive care. The aim of the current study was to develop a guinea pig model to evaluate the efficacy of delayed treatment following nerve agent exposure. We identified a trigger-to-treat based on a progressive stage of the toxidrome following VX exposure, which was associated with the subsiding of clonic movements. This paradigm resulted in treatment consistently being administered between 15 and 25 min post-exposure. Using the model, we investigated the potential for the anticholinergic scopolamine to act as a delayed treatment either as a standalone treatment, or as an adjunct to delayed treatment with Standard of Care (SOC), containing atropine, 2-PAM, and midazolam. The study provides a framework for a small animal model for evaluating the efficacy of treatment administered at a specific stage of the toxidrome, when immediate treatment is absent. As an adjunct, scopolamine treatment did not result in improved survival, but did show a beneficial effect on recovery, in terms of general posture. As a standalone treatment, scopolamine showed a significant, dose-responsive, beneficial effect on survival and recovery. These promising results warrant additional studies to investigate which observed physiological improvements are relevant for the recovery process and residual injury.


Subject(s)
Chemical Warfare Agents/toxicity , Cholinergic Antagonists/administration & dosage , Nerve Agents/toxicity , Organothiophosphorus Compounds/toxicity , Scopolamine/administration & dosage , Time-to-Treatment , Animals , Atropine/administration & dosage , Dose-Response Relationship, Drug , Drug Evaluation, Preclinical/methods , Drug Therapy, Combination , Guinea Pigs , Male , Midazolam/administration & dosage , Pralidoxime Compounds/administration & dosage , Survival Rate/trends
2.
ScientificWorldJournal ; 2021: 6649574, 2021.
Article in English | MEDLINE | ID: mdl-33994883

ABSTRACT

Garugapinnata Roxb. (Burseraceae) is a medium-sized tree widely available all over the tropical regions of Asia. Bryophyllum pinnatum (Lam) Oken. (Crassulaceae) is an indigenous and exotic plant grown in tropical regions. Both plants have been used for their anti-inflammatory, antioxidant, anticancer, wound healing, antidiabetic activities, etc. This investigation was designed to explore the result shown by methanolic extract of Garuga pinnata bark and Bryophyllum pinnatum leaves, on cognitive power and retention of the memory in experimental mice along with quantification of phenolic compounds and DPPH radicals neutralizing capacity. The memory-enhancing activity was determined by the elevated plus-maze method in Scopolamine-induced amnesic mice, using Piracetam as allopathic and Shankhpushpi as ayurvedic standard drugs. Two doses (200 and 400 mg/kg p.o.) of both extracts were administered to mice up to 8 consecutive days; transfer latency of individual group was recorded after 45 minutes and memory of the experienced things was examined after 1 day. DPPH assay method and the Folin-Ciocalteu method were employed to determine antioxidant potency and total phenol amount, respectively. 400 mg/kg of the methanolic B. pinnatum bark extract significantly improved memory and learning of mice with transfer latency (TL) of 32.75 s, which is comparable to that of standard Piracetam (21.78 s) and Shankhpushpi (27.83 s). Greater phenolic content was quantified in B. pinnatum bark extract (156.80 ± 0.33 µg GAE/mg dry extract) as well as the antioxidant potency (69.77% of free radical inhibition at the 100 µg/mL concentration). Our study proclaimed the scientific evidence for the memory-boosting effect of both plants.


Subject(s)
Amnesia/drug therapy , Antioxidants/pharmacology , Burseraceae/chemistry , Kalanchoe/chemistry , Nootropic Agents/pharmacology , Phytochemicals/pharmacology , Amnesia/chemically induced , Amnesia/physiopathology , Animals , Antioxidants/isolation & purification , Biphenyl Compounds/antagonists & inhibitors , Cognition/drug effects , Cognition/physiology , Female , Male , Maze Learning/drug effects , Maze Learning/physiology , Memory/drug effects , Memory/physiology , Mice , Nootropic Agents/isolation & purification , Phenols/pharmacology , Phytochemicals/isolation & purification , Picrates/antagonists & inhibitors , Piracetam/pharmacology , Plant Bark/chemistry , Plant Extracts/chemistry , Plant Leaves/chemistry , Plant Preparations/pharmacology , Scopolamine/administration & dosage
3.
Behav Brain Res ; 378: 112314, 2020 01 27.
Article in English | MEDLINE | ID: mdl-31644927

ABSTRACT

Alzheimer's disease (AD) is a neurodegenerative disease characterized by cognitive and memory problems. Scopolamine (SCOP) is a natural anticholinergic drug that was proven to cause memory impairment in rats. Chelating agents are potential neuroprotective and memory enhancing agents as they can trap iron that enters in pathological deposition of ß-amyloid (Aß) which is a hallmark in AD and memory disorders. This study investigated the potential neuroprotective and memory enhancing effects of the iron chelating drug, Deferiprone. Three doses (5, 10, and 20 mg/kg) were administered to rats treated with SCOP (1.14 mg/kg/day). Systemic administration of SCOP for seven days caused memory impairment which manifested as decreased time spent in platform quadrant in Morris water maze test, decreased retention latencies in passive avoidance test, and increased acetylcholinesterase (AChE) activity, Aß, and free iron deposition. It was observed that pretreatment with Deferiprone increased platform quadrant time in Morris water maze and increased retention latencies in the passive avoidance test. It also attenuated the increase in AChE activity and decreased Aß and iron deposition. Overall, Deferiprone (10 mg/kg) was determined as the most effective dose. Therefore, this study suggests neuroprotective and memory enhancing effects for Deferiprone in SCOP-treated rats which might be attributed to its iron chelating action and anti-oxidative effect.


Subject(s)
Amyloid beta-Peptides/metabolism , Cholinergic Antagonists/pharmacology , Deferiprone/pharmacology , Iron Chelating Agents/pharmacology , Memory Disorders/chemically induced , Memory Disorders/drug therapy , Memory Disorders/metabolism , Neuroprotective Agents/pharmacology , Nootropic Agents/pharmacology , Scopolamine/pharmacology , Animals , Behavior, Animal/drug effects , Cholinergic Antagonists/administration & dosage , Deferiprone/administration & dosage , Iron/metabolism , Iron Chelating Agents/administration & dosage , Male , Neuroprotective Agents/administration & dosage , Nootropic Agents/administration & dosage , Rats , Scopolamine/administration & dosage , Staining and Labeling
4.
Pharmacol Biochem Behav ; 187: 172792, 2019 12.
Article in English | MEDLINE | ID: mdl-31593740

ABSTRACT

Murine strain differences occur for both intakes of and preferences for sugars and fats. Previous studies demonstrated that the muscarinic cholinergic receptor antagonist, scopolamine (SCOP) more potently reduced sucrose and saccharin intakes in inbred C57BL/6 and BALB/c than SWR mice, sucrose-conditioned flavor preferences (CFP) expression in BALB/c, but not C57BL/6 or SWR mice, and sucrose-CFP acquisition in BALB/c relative to SWR and C57BL/6 mice. Although fat intake and fat-CFP are observed in all three strains, strain-specific effects were previously observed following dopamine D1, opiate and NMDA receptor antagonism of sweet and fat intake and CFP. The present study investigated whether muscarinic receptor antagonism differentially affected fat (Intralipid) intake and preferences in these strains by examining whether SCOP altered fat (Intralipid) intake and fat-CFP expression and acquisition in BALB/c, C57BL/6 and SWR mice. SCOP (0.1-10 mg/kg) significantly reduced Intralipid (5%) intake in all three strains across 2 h. In fat-CFP expression experiments, food-restricted mice consumed one flavored (conditioned stimulus (CS)+, 5 sessions) Intralipid (5%) solution and a differently-flavored (CS-, 5 sessions) Intralipid (0.5%) solution. Two-bottle CS choice tests with the two flavors mixed in 0.5% Intralipid occurred following vehicle and two SCOP doses (1, 5 mg/kg). SCOP elicited small, but significant reductions in fat-CFP expression in BALB/c and C57BL/6, but not SWR mice. In fat-CFP acquisition experiments, separate groups of BALB/c, C57BL/6 and SWR mice were treated prior to the ten acquisition training sessions with vehicle or two SCOP (2.5, 5 mg/kg) doses followed by six two-bottle choice tests without injections. SCOP eliminated fat-CFP acquisition in all three strains. Thus, muscarinic receptor signaling mediates learning, and to a lesser degree maintenance of fat-CFP while maximally inhibiting fat intake in the three strains.


Subject(s)
Flavoring Agents/administration & dosage , Food Preferences/drug effects , Muscarinic Antagonists/pharmacology , Phospholipids/administration & dosage , Receptors, Muscarinic/metabolism , Scopolamine/pharmacology , Soybean Oil/administration & dosage , Taste/drug effects , Administration, Oral , Animals , Conditioning, Classical/drug effects , Conditioning, Classical/physiology , Emulsions/administration & dosage , Male , Mice , Mice, Inbred BALB C , Mice, Inbred C57BL , Muscarinic Antagonists/administration & dosage , Scopolamine/administration & dosage
5.
Int J Neurosci ; 129(12): 1203-1212, 2019 Dec.
Article in English | MEDLINE | ID: mdl-31393204

ABSTRACT

Purpose of the study: Kaempferol (KM) is a flavonoid found in plant-derived foods and medicinal plants. Recently, it is well established that KM plays a protective role to develop Alzheimer's disease. The current study aimed at evaluating the effect of intracerebroventricular micro-injection of KM on memory retention of passive avoidance learning (MRPAM) and identifying the potentially related cholinergic mechanisms (ChMs) in rats. Materials and methods: In the current study, male Wistar rats randomly divided into control, vehicle and KM (10, 20 and 40 µg/rat) groups. Moreover, MRPAM was evaluated by shuttle box test. The role of ChM was studied using non-selective and selective acetylcholine antagonists (scopolamine [SCN], 4-DAMP and methoctramine [MN], respectively) as well as pirenzepine (PZ) in combination with KM. Results: The employment of KM (40 µg/rat) improved the SCN-induced memory impairment in MRPAM. Co-treatment with KM (40 µg/rat) plus 4-DAMP significantly increased the step-through latency (STL, P < 0.05; 167 ± 28 s) and decreased the total dark chamber (TDC, P < 0.05; 121 ± 31 s) compared with those of the 4-DAMP group (STL: 75 ± 13 s; TDC: 178 ± 46 s). Co-treatment with KM (40 µg/rat) plus PZ attenuated STL, and also increased TDC (P < 0.01; 220 ± 28 s) compared with those of the PZ group. Co-treatment with KM (10 and 20 µg/rat) and MN increased STL (P < 0.05), and deceased TDC compared with those of the MN group (P < 0.01). Conclusions: Totally, the results of the present study showed that cholinergic system may be involved in improving effect of KM on SCN-induced memory impairment.


Subject(s)
Acetylcholine/physiology , Avoidance Learning/drug effects , Cholinergic Antagonists/administration & dosage , Kaempferols/administration & dosage , Memory/drug effects , Muscarinic Antagonists/administration & dosage , Animals , Avoidance Learning/physiology , Diamines/administration & dosage , Injections, Intraventricular , Male , Memory/physiology , Microinjections , Piperidines/administration & dosage , Pirenzepine/administration & dosage , Rats, Wistar , Scopolamine/administration & dosage
6.
Food Funct ; 9(3): 1424-1432, 2018 Mar 01.
Article in English | MEDLINE | ID: mdl-29431777

ABSTRACT

Flammulina velutipes polysaccharides (FVP) have been proved to be effective in improving learning and memory impairment in mice. However, their underlying mechanism remains unclear. The aim of this study was to investigate the relationship between memory improvement and gut microbiota regulation of FVP. The results showed a significant decrease in the relative abundances of Clostridia and Bacilli but a significant increase in Bacteroidia, Erysipelotrichia and Actinobacteria in the FVP-treated group versus the control group. Fecal microbiota transplantation of mice with 'FVP microbiota' derived from FVP-fed mice resulted in improved learning and memory function compared to colonization with 'common microbiota' derived from control individuals. FVP and 'FVP microbiota' significantly increased the numbers of platform crossings and the swimming distance of mice in the probe test and decreased the escape latency and total swimming distance of mice in the hidden platform test. Moreover, FVP and 'FVP microbiota' regulated cytokines, such as IL-1ß, TNF-α, IL-6 and IL-10, suggesting a mechanism involving the suppression of neuroinflammation. This study indicated that the regulation of the gut microbiome may have a causal role in improving scopolamine-induced impairment of learning and memory.


Subject(s)
Cognitive Dysfunction/drug therapy , Cognitive Dysfunction/microbiology , Flammulina/chemistry , Gastrointestinal Microbiome/drug effects , Plant Extracts/administration & dosage , Polysaccharides/administration & dosage , Scopolamine/administration & dosage , Animals , Bacteria/classification , Bacteria/drug effects , Bacteria/genetics , Bacteria/isolation & purification , Cognitive Dysfunction/psychology , Feces/microbiology , Humans , Interleukin-10/genetics , Interleukin-10/metabolism , Interleukin-1beta/genetics , Interleukin-1beta/metabolism , Interleukin-6/genetics , Interleukin-6/metabolism , Male , Maze Learning/drug effects , Memory/drug effects , Mice , Mice, Inbred C57BL , Tumor Necrosis Factor-alpha/genetics , Tumor Necrosis Factor-alpha/metabolism
7.
Arch Pharm Res ; 40(10): 1209-1217, 2017 Oct.
Article in English | MEDLINE | ID: mdl-28940173

ABSTRACT

Liquiritigenin (LQ), a flavonoid extracted from the radix of Glycyrrhiza, has anti-inflammatory and neuroprotective properties. In this study, we evaluated the cognitive enhancing effects of LQ on learning and memory impairments induced by scopolamine (0.5 mg/kg, i.p.), a muscarinic antagonist, using the Y-maze, passive avoidance, and novel object recognition tests. A single administration of LQ significantly improved scopolamine-induced cognitive impairments in these behavioral tests. In addition, LQ dramatically inhibited acetylcholinesterase and thiobarbituric acid reactive substance activities in the hippocampus of scopolamine-induced mice in a dose-dependent manner. Furthermore, LQ markedly increased the protein level of brain-derived neurotrophic factor (BDNF) and phosphorylation of extracellular signal-regulated kinase (ERK) and cAMP response element binding (CREB) in the hippocampus of scopolamine-induced mice. Taken together, our results indicate that LQ may be useful for the treatment of learning and memory impairments, and that the beneficial effects of LQ are mediated, in part, by cholinergic and BDNF/ERK/CREB signaling enhancement and/or protection.


Subject(s)
Acetylcholinesterase/metabolism , Brain-Derived Neurotrophic Factor/metabolism , Cognitive Dysfunction/prevention & control , Flavanones/therapeutic use , Hippocampus/drug effects , Memory Disorders/prevention & control , Neuroprotective Agents/therapeutic use , Animals , Behavior, Animal/drug effects , Cognitive Dysfunction/metabolism , Disease Models, Animal , Flavanones/isolation & purification , Hippocampus/metabolism , Male , Memory Disorders/metabolism , Mice, Inbred Strains , Neuroprotective Agents/isolation & purification , Scopolamine/administration & dosage
8.
Am J Alzheimers Dis Other Demen ; 32(7): 418-428, 2017 Nov.
Article in English | MEDLINE | ID: mdl-28643520

ABSTRACT

Alzheimer's disease leads to progressive cognitive function loss, which may impair both intellectual capacities and psychosocial aspects. Although the current knowledge points to a multifactorial character of Alzheimer's disease, the most issued pathological hypothesis remains the cholinergic theory. The main animal model used in cholinergic theory research is the scopolamine-induced memory loss model. Although, in some cases, a temporary symptomatic relief can be obtained through targeting the cholinergic or glutamatergic neurotransmitter systems, no current treatment is able to stop or slow cognitive impairment. Many potentially successful therapies are often blocked by the blood-brain barrier since it exhibits permeability only for several classes of active molecules. However, the plant extracts' active molecules are extremely diverse and heterogeneous regarding the biochemical structure. In this way, many active compounds constituting the recently tested plant extracts may exhibit the same general effect on acetylcholine pathway, but on different molecular ground, which can be successfully used in Alzheimer's disease adjuvant therapy.


Subject(s)
Memory Disorders/chemically induced , Plant Extracts/administration & dosage , Scopolamine , Animals , Blood-Brain Barrier/metabolism , Brain/metabolism , Cognition/drug effects , Disease Models, Animal , Humans , Scopolamine/administration & dosage , Scopolamine/adverse effects
9.
Curr Drug Targets ; 18(13): 1545-1557, 2017.
Article in English | MEDLINE | ID: mdl-28302036

ABSTRACT

BACKGROUND: Stress is involved in memory impairment through multiple mechanisms, including activation of hypothalamic-pituitary axis, which in turn activates release of corticosterone in blood. Cholinergic system blockade by the muscarinic antagonist, scopolamine, also impairs memory. OBJECTIVE: This study aimed to investigate the effect of turmeric (20mg/kg) on learning and memory and cholinergic system in a mouse model of stress along with cholinergic blockade. METHODS: Restrained stress was induced and cholinergic receptors were blocked using scopolamine in mice. Animals were treated with turmeric (turmeric rhizome powder which was also subjected to NMR analyses) and learning and social behavior was examined. Effect of turmeric on cholinergic muscarinic receptors (mAChR; M1, M3 and M5) gene expression was assessed by RT-PCR in both pre-frontal cortex and hippocampus. RESULTS: Ar-turmerone, curcuminoids and α-linolenic acid were the lead compounds present in turmeric extract. Increased serum corticosterone levels were observed in stressed mice when compared to the control group, while turmeric treatment significantly reduced serum corticosterone level. Turmeric treatment caused an improved learning and memory in Morris water maze test in stressed animals. Social novelty preference was also restored in turmeric treated animals. Following turmeric treatment, M5 expression was improved in the cortex and M3 expression was improved in the hippocampus of stress + scopolamine + turmeric treated group. CONCLUSIONS: These findings highlight the therapeutic role of turmeric by increasing the expression of M3, M5 and improving learning and memory. Turmeric can be an effective candidate for the treatment of amnesia caused by the stress.


Subject(s)
Plant Extracts/administration & dosage , Receptors, Muscarinic/metabolism , Scopolamine/administration & dosage , Stress, Psychological/drug therapy , Animals , Behavior, Animal/drug effects , Curcuma/chemistry , Disease Models, Animal , Learning/drug effects , Male , Memory/drug effects , Mice , Plant Extracts/chemistry , Plant Extracts/pharmacology , Scopolamine/pharmacology , Stress, Psychological/psychology
10.
Food Funct ; 8(4): 1460-1467, 2017 Apr 19.
Article in English | MEDLINE | ID: mdl-28275781

ABSTRACT

Aqueous extracts from Asparagus officinalis L. stems (AEAS) are rich in polysaccharides, gamma-amino butyric acid (GABA), and steroidal saponin. This study was designed to investigate the effects of AEAS on learning, memory, and acetylcholinesterase-related activity in a scopolamine-induced model of amnesia. Sixty ICR mice were randomly divided into 6 groups (n = 10) including the control group (CT), scopolamine group (SC), donepezil group (DON), low, medium, and high dose groups of AEAS (LS, MS, HS; 1.6 mL kg-1, 8 mL kg-1, 16 mL kg-1). The results showed that 8 mL kg-1 of AEAS used in this study significantly reversed scopolamine-induced cognitive impairments in mice in the novel object recognition test (P < 0.05) and the Y-maze test (P < 0.05), and also improved the latency to escape in the Morris water maze test (P < 0.05). Moreover, it significantly increased acetylcholine and inhibited acetylcholinesterase activity in the hippocampus, which was directly related to the reduction in learning and memory impairments. It also reversed scopolamine-induced reduction in the hippocampal brain-derived neurotrophic factor (BDNF) and the cAMP response element-binding protein (CREB) mRNA expression. AEAS protected against scopolamine-induced memory deficits. In conclusion, AEAS protected learning and memory function in mice by enhancing the activity of the cholinergic nervous system, and increasing BDNF and CREB expression. This suggests that AEAS has the potential to prevent cognitive impairments in age-related diseases, such as Alzheimer's disease.


Subject(s)
Amnesia/drug therapy , Asparagus Plant/chemistry , Memory/drug effects , Plant Extracts/administration & dosage , Scopolamine/administration & dosage , Amnesia/chemically induced , Amnesia/metabolism , Amnesia/psychology , Animals , Brain-Derived Neurotrophic Factor/genetics , Brain-Derived Neurotrophic Factor/metabolism , Cyclic AMP Response Element-Binding Protein/genetics , Cyclic AMP Response Element-Binding Protein/metabolism , Hippocampus/drug effects , Hippocampus/metabolism , Humans , Male , Mice , Mice, Inbred ICR
11.
Mol Neurobiol ; 54(4): 2852-2868, 2017 05.
Article in English | MEDLINE | ID: mdl-27021021

ABSTRACT

Inhibition of Ca2+ entry into the hippocampus and dorsal root ganglion (DRG) through inhibition of N-methyl-D-aspartate (NMDA) receptor antagonist drugs is the current standard of care in neuronal diseases such as Alzheimer's disease, dementia, and peripheral pain. Oxidative stress activates Ca2+-permeable TRPM2 and TRPV1, and recent studies indicate that selenium (Se) is a potent TRPM2 and TRPV1 channel antagonist in the hippocampus and DRG. In this study, we investigated the neuroprotective properties of Se in primary hippocampal and DRG neuron cultures of aged rats when given alone or in combination with scopolamine (SCOP). Thirty-two aged (18-24 months old) rats were divided into four groups. The first and second groups received a placebo and SCOP (1 mg/kg/day), respectively. The third and fourth groups received intraperitoneal Se (1.5 mg/kg/ over day) and SCOP + Se, respectively. The hippocampal and DRG neurons also were stimulated in vitro with a TRPV1 channel agonist (capsaicin) and a TRPM2 channel agonist (cumene hydroperoxide). We found that Se was fully effective in reversing SCOP-induced TRPM2 and TRPV1 current densities as well as errors in working memory and reference memory. In addition, Se completely reduced SCOP-induced oxidative toxicity by modulating lipid peroxidation, reducing glutathione and glutathione peroxidase. The Se and SCOP + Se treatments also decreased poly (ADP-ribose) polymerase activity, intracellular free Ca2+ concentrations, apoptosis, and caspase 3, caspase 9, and mitochondrial membrane depolarization values in the hippocampus. In conclusion, the current study reports on the cellular level for SCOP and Se on the different endocytotoxic cascades for the first time. Notably, the research indicates that Se can result in remarkable neuroprotective and memory impairment effects in the hippocampal neurons of rats. Graphical abstract Possible molecular pathways of involvement of selenium (Se) in scopolamine (SCOP) induced apoptosis, oxidative stress, and calcium accumulation through TRPM2 and TRPV1 channels in the hippocampus neurons of aged rats. The TRPM2 channel is activated by ADP-ribose and oxidative stress, although it is inhibited by ACA. The TRPV1 channel is activated by oxidative stress and capsaicin, and it is blocked by capsazepine (CPZ). The beta-amyloid plaque induces oxidative stress in hippocampus. SCOP can result in augmented ROS release in hippocampal neurons, leading to Ca2+ uptake through TRPM2 and TRPV1 channels. Mitochondria were reported to accumulate Ca2+ provided that intracellular Ca2+ rises, thereby leading to the depolarization of mitochondrial membranes and release of apoptosis-inducing factors such as caspase 3 and caspase 9. Se reduced TRPM2 and TRPV1 channel activation through the modulation of aging oxidative reactions and Se-dependent glutathione peroxidase (GSH-Px) antioxidant pathways.


Subject(s)
Aging/pathology , Apoptosis , Memory Disorders/drug therapy , Neuroprotective Agents/therapeutic use , Oxidative Stress , Selenium/therapeutic use , TRPM Cation Channels/metabolism , TRPV Cation Channels/metabolism , Animals , Apoptosis/drug effects , Calcium/metabolism , Caspase 3/metabolism , Caspase 9/metabolism , Female , Ganglia, Spinal/drug effects , Ganglia, Spinal/metabolism , Ganglia, Spinal/pathology , Ganglia, Spinal/physiopathology , Glutathione/metabolism , Glutathione Peroxidase/metabolism , Hippocampus/drug effects , Hippocampus/metabolism , Hippocampus/pathology , Hippocampus/physiopathology , Intracellular Space/metabolism , Ion Channel Gating/drug effects , Lipid Peroxidation/drug effects , Maze Learning/drug effects , Membrane Potential, Mitochondrial/drug effects , Memory Disorders/pathology , Memory Disorders/physiopathology , Memory, Short-Term/drug effects , Neurons/drug effects , Neurons/enzymology , Neurons/pathology , Neuroprotective Agents/pharmacology , Oxidative Stress/drug effects , Poly(ADP-ribose) Polymerases/metabolism , Rats, Wistar , Reactive Oxygen Species/metabolism , Scopolamine/administration & dosage , Selenium/pharmacology
12.
Urology ; 100: 27-32, 2017 Feb.
Article in English | MEDLINE | ID: mdl-27658661

ABSTRACT

OBJECTIVE: To investigate whether the use of a belladonna and opium (B&O) rectal suppository administered immediately before ureteroscopy (URS) and stent placement could reduce stent-related discomfort. METHODS: A randomized, double-blinded, placebo-controlled study was performed from August 2013 to December 2014. Seventy-one subjects were enrolled and randomized to receive a B&O (15 mg/30 mg) or a placebo suppository after induction of general anesthesia immediately before URS and stent placement. Baseline urinary symptoms were assessed using the American Urological Association Symptom Score (AUASS). The Ureteral Stent Symptom Questionnaire and AUASS were completed on postoperative days (POD) 1, 3, and after stent removal. Analgesic use intraoperatively, in the recovery unit, and at home was recorded. RESULTS: Of the 71 subjects, 65 had treatment for ureteral (41%) and renal (61%) calculi, 4 for renal urothelial carcinoma, and 2 were excluded for no stent placed. By POD3, the B&O group reported a higher mean global quality of life (QOL) score (P = .04), a better mean quality of work score (P = .05), and less pain with urination (P = .03). The B&O group reported an improved AUASS QOL when comparing POD1 with post-stent removal (P = .04). There was no difference in analgesic use among groups (P = .67). There were no episodes of urinary retention. Age was associated with unplanned emergency visits (P <.00) and "high-pain" measure (P = .02) CONCLUSION: B&O suppository administered preoperatively improved QOL measures and reduced urinary-related pain after URS with stent. Younger age was associated with severe stent pain and unplanned hospital visits.


Subject(s)
Atropa belladonna , Atropine/administration & dosage , Opium/administration & dosage , Pain, Postoperative/prevention & control , Scopolamine/administration & dosage , Stents/adverse effects , Ureteroscopy/adverse effects , Adjuvants, Anesthesia/administration & dosage , Adult , Aged , Analgesics, Opioid/administration & dosage , Double-Blind Method , Female , Humans , Male , Middle Aged , Pain, Postoperative/etiology , Parasympatholytics/administration & dosage , Phytotherapy , Plant Extracts/administration & dosage , Preoperative Care , Prospective Studies , Quality of Life , Suppositories , Urinary Calculi/surgery
13.
Neuropharmacology ; 113(Pt A): 100-109, 2017 02.
Article in English | MEDLINE | ID: mdl-27470063

ABSTRACT

Oleanolic acid is a naturally occurring triterpenoid and is widely present in food and medicinal plants. To examine the effect of oleanolic acid on memory deficits, we employed a cholinergic blockade-induced cognitive deficit mouse model. A single administration of oleanolic acid significantly increased the latency on the passive avoidance task and affected the alternation behavior on the Y-maze task and the exploration time on the novel object recognition task, indicating that oleanolic acid reverses the cognitive impairment induced by scopolamine. In accordance with previous reports, oleanolic acid enhanced extracellular-signal-regulated kinase 1/2 (ERK1/2) and cAMP response element-binding protein (CREB) phosphorylation and brain-derived neurotrophic factor (BDNF) expression in the hippocampus. Interestingly, ameliorating effect of oleanolic acid on scopolamine-induced memory impairment was abolished by N2-(2-{[(2-oxoazepan-3-yl)amino]carbonyl}phenyl)benzo[b]thiophene-2-carboxamide (ANA-12), a potent and specific inhibitor of tropomyosin receptor kinase B (TrkB), in the passive avoidance task. Similarly, oleanolic acid significantly evoked long-term potentiation in a dose-dependent manner, which was diminished by ANA-12 treatment as shown in the electrophysiology study. Together, these results imply that oleanolic acid ameliorates scopolamine-induced memory impairment by modulating the BDNF-ERK1/2-CREB pathway through TrkB activation in mice, suggesting that oleanolic acid would be a potential therapeutic agent for the treatment of cognitive deficits.


Subject(s)
Acetylcholine/metabolism , Brain-Derived Neurotrophic Factor/metabolism , Cognitive Dysfunction/metabolism , Cognitive Dysfunction/psychology , Oleanolic Acid/administration & dosage , Receptor, trkB/metabolism , Animals , Avoidance Learning/drug effects , Cholinergic Antagonists/administration & dosage , Cognitive Dysfunction/chemically induced , Cyclic AMP Response Element-Binding Protein/metabolism , Hippocampus/drug effects , Hippocampus/metabolism , Long-Term Potentiation/drug effects , MAP Kinase Signaling System/drug effects , Male , Maze Learning/drug effects , Mice , Mice, Inbred ICR , Recognition, Psychology/drug effects , Scopolamine/administration & dosage , Signal Transduction/drug effects
14.
Toxicol Ind Health ; 31(6): 494-509, 2015 Jun.
Article in English | MEDLINE | ID: mdl-23406953

ABSTRACT

The study determined the maximum intraperitoneal (ip) scopolamine dose inducing memory impairment in rats (2 mg/kg) compared to 0.5 or 1 mg/kg dose. The effect reflected by significant increase from normal in the latency time required for rats to find the hidden platform in water maze task and acetylcholinesterase (AChE) activities in cortex, hippocampus and striatum. The dose-related histopathological effect via the hemorrhage, vacuolation and gliosis in cortex and hippocampus is assessed. Then the study investigated the potency of Panax ginseng root extract on scopolamine cognitive dysfunction rat model compared to memantine hydrochloride as reference Food and Drug Administration approved. Ginseng extract was administered at dose 100 or 200 mg/kg/day and memantine at 20 mg/kg/day orally for 2 weeks. All treatments showed improvement in the water maze task, however, ginseng (200 mg/kg) group acquired the advantage without statistical difference control. Scopolamine (2 mg/kg ip) group showed significant increase in AChE reactivity and glutamate level and reduced monoamines (norepinephrine, dopamine and serotonin) and γ-aminobutyric acid contents in cortex, hippocampus and striatum. Ginseng extract in a dose-dependent manner appears effective as memantine and can improve memory impairment through the retrieved homeostasis via neurotransmitter levels and AChE activities in rat brain areas with partial effect on the histological feature of the brain tissue.


Subject(s)
Memantine/pharmacology , Memory Disorders/drug therapy , Panax , Plant Extracts/pharmacology , Acetylcholinesterase/metabolism , Animals , Brain/drug effects , Dopamine/metabolism , Dose-Response Relationship, Drug , Gliosis/metabolism , Memantine/administration & dosage , Norepinephrine/metabolism , Plant Extracts/administration & dosage , Plant Roots , Rats , Scopolamine/administration & dosage , Scopolamine/pharmacology , Serotonin/metabolism , gamma-Aminobutyric Acid/metabolism
15.
PLoS One ; 9(2): e88076, 2014.
Article in English | MEDLINE | ID: mdl-24505383

ABSTRACT

Lycium barbarum is used both as a food additive and as a medicinal herb in many countries, and L. barbarum polysaccharides (LBPs), a major cell component, are reported to have a wide range of beneficial effects including neuroprotection, anti-aging and anticancer properties, and immune modulation. The effects of LBPs on neuronal function, neurogenesis, and drug-induced learning and memory deficits have not been assessed. We report the therapeutic effects of LBPs on learning and memory and neurogenesis in scopolamine (SCO)-treated rats. LBPs were administered via gastric perfusion for 2 weeks before the onset of subcutaneous SCO treatment for a further 4 weeks. As expected, SCO impaired performance in novel object and object location recognition tasks, and Morris water maze. However, dual SCO- and LBP-treated rats spent significantly more time exploring the novel object or location in the recognition tasks and had significant shorter escape latency in the water maze. SCO administration led to a decrease in Ki67- or DCX-immunoreactive cells in the dentate gyrus and damage of dendritic development of the new neurons; LBP prevented these SCO-induced reductions in cell proliferation and neuroblast differentiation. LBP also protected SCO-induced loss of neuronal processes in DCX-immunoreactive neurons. Biochemical investigation indicated that LBP decreased the SCO-induced oxidative stress in hippocampus and reversed the ratio Bax/Bcl-2 that exhibited increase after SCO treatment. However, decrease of BDNF and increase of AChE induced by SCO showed no response to LBP administration. These results suggest that LBPs can prevent SCO-induced cognitive and memory deficits and reductions in cell proliferation and neuroblast differentiation. Suppression of oxidative stress and apoptosis may be involved in the above effects of LBPs that may be a promising candidate to restore memory functions and neurogenesis.


Subject(s)
Adjuvants, Anesthesia/pharmacology , Antioxidants/pharmacology , Drugs, Chinese Herbal/pharmacology , Neurogenesis/drug effects , Neuroprotective Agents/pharmacology , Scopolamine/pharmacology , Adjuvants, Anesthesia/administration & dosage , Adjuvants, Anesthesia/toxicity , Animals , Antioxidants/administration & dosage , Apoptosis/drug effects , Doublecortin Protein , Drugs, Chinese Herbal/administration & dosage , Hippocampus/cytology , Hippocampus/drug effects , Lycium/chemistry , Male , Maze Learning/drug effects , Memory/drug effects , Neuroprotective Agents/administration & dosage , Rats , Rats, Sprague-Dawley , Scopolamine/administration & dosage , Scopolamine/toxicity
16.
Masui ; 62(2): 239-43, 2013 Feb.
Article in Japanese | MEDLINE | ID: mdl-23479935

ABSTRACT

There have been some records of labor analgesia with intravenous or rectal anesthetics in early Showa-period (1926-1989). However, the author found that labor analgesia had been already attempted for some women in late Meiji-period (1868-1912). One of agents used was pantopon, a water-soluble opioid without serious respiratory depression as morphine. The drug was developed and produced in Germany. Some doctors applied this agent with scopolamine to labor analgesia in Europe. They also reported that this combination also conferred excellent analgesic effects without any serious complications in the mother and fetus. This combination was originally used for general surgery with inhaled anesthesia at that period. It remains uncertain how Japanese doctors got pantopon scopolamine from Germany.


Subject(s)
Adjuvants, Anesthesia/administration & dosage , Analgesia, Obstetrical/history , Analgesics, Opioid/administration & dosage , Opium/administration & dosage , Scopolamine/administration & dosage , Famous Persons , Female , History, 19th Century , History, 20th Century , Humans , Japan , Literature/history , Pregnancy
17.
Phytother Res ; 26(6): 884-91, 2012 Jun.
Article in English | MEDLINE | ID: mdl-22086772

ABSTRACT

Although plant-derived essential oils (EOs) have been used to treat various mental disorders, their central nervous system (CNS) acting effects have not been clarified. The present study compared the effects of 20 kinds of EOs with the effects of already-known CNS acting drugs to examine whether the EOs exhibited CNS stimulant-like effects, CNS depressant-like effects, or neither. All agents were tested using a discrete shuttle-type conditioned avoidance task in mice. Essential oils of peppermint and chamomile exhibited CNS stimulant-like effects; that is, they increased the response rate (number of shuttlings/min) of the avoidance response. Linden also increased the response rate, however, the effect was not dose-dependent. In contrast, EOs of orange, grapefruit, and cypress exhibited CNS depressant-like effects; that is, they decreased the response rate of the avoidance response. Essential oils of eucalyptus and rose decreased the avoidance rate (number of avoidance responses/number of avoidance trials) without affecting the response rate, indicating that they may exhibit some CNS acting effects. Essential oils of 12 other plants, including juniper, patchouli, geranium, jasmine, clary sage, neroli, lavender, lemon, ylang-ylang, niaouli, vetivert and frankincense had no effect on the avoidance response in mice.


Subject(s)
Avoidance Learning/drug effects , Behavior, Animal , Central Nervous System/drug effects , Conditioning, Psychological/drug effects , Oils, Volatile/pharmacology , Animals , Central Nervous System Stimulants/administration & dosage , Central Nervous System Stimulants/chemistry , Central Nervous System Stimulants/pharmacology , Chamomile/chemistry , Dose-Response Relationship, Drug , Drug Evaluation, Preclinical , Eucalyptus/chemistry , Injections, Intraperitoneal , Injections, Subcutaneous , Male , Mentha piperita/chemistry , Mice , Oils, Volatile/administration & dosage , Oils, Volatile/chemistry , Phenethylamines/administration & dosage , Phenethylamines/pharmacology , Plant Oils/administration & dosage , Plant Oils/chemistry , Plant Oils/pharmacology , Rosa/chemistry , Scopolamine/administration & dosage , Scopolamine/pharmacology , Tilia/chemistry
18.
Zhong Yao Cai ; 34(9): 1403-5, 2011 Sep.
Article in Chinese | MEDLINE | ID: mdl-22260011

ABSTRACT

OBJECTIVE: To study the effect of extracts of Cordyceps sinensis sporocarp on learning-memory in scopolamine treated mice and the possible mechanism. METHODS: ICR mice were randomly divided into five groups: sham control, model, piracetam and CSE 0.5, 1 g/kg. Lotomotor activity was assessed. Morris water maze was used to evaluate the memory ability of mice 30 min later after ip scopolamine 1.0 mg/kg BW. Then acitivity of AchE was measured after behavioral test. RESULTS: CSE had no influence on lotomotor activity. However, CSE 0.5, 1 g/kg both shortened escape latency and increased times of come-crossing platform in Morris water maze, meanwhile activity of AchE in the brain was decreased by CSE. CONCLUSION: CSE can significantly improve the learning and memory impairment in mice induced by scopolamine, which may be correlated with the inhibition of activity of AchE.


Subject(s)
Cordyceps/chemistry , Drugs, Chinese Herbal/pharmacology , Learning Disabilities/drug therapy , Memory Disorders/drug therapy , Nootropic Agents/pharmacology , Acetylcholinesterase/metabolism , Animals , Behavior, Animal/drug effects , Brain/drug effects , Brain/metabolism , Cognition , Dose-Response Relationship, Drug , Drugs, Chinese Herbal/isolation & purification , Drugs, Chinese Herbal/therapeutic use , Female , Learning Disabilities/chemically induced , Male , Maze Learning/drug effects , Memory/drug effects , Memory Disorders/chemically induced , Mice , Mice, Inbred ICR , Motor Activity/drug effects , Random Allocation , Scopolamine/administration & dosage
19.
Can J Urol ; 17(5): 5377-82, 2010 Oct.
Article in English | MEDLINE | ID: mdl-20974030

ABSTRACT

INTRODUCTION: Robotic assisted laparoscopic radical prostatectomy (RALP) is a common treatment for localized prostate cancer. Despite a primary advantage of improved postoperative pain, patients undergoing RALP still experience discomfort. Belladonna, containing the muscarinic receptor antagonists atropine and scopolamine, in combination with opium as a rectal suppository (B & O) may improve post-RALP pain. This study evaluates whether a single preoperative B & O results in decreased postoperative patient-reported pain and analgesic requirements. MATERIALS AND METHODS: Patients undergoing RALP at Virginia Mason Medical Center between November 2008 and July 2009 were offered the opportunity to enter a randomized, double-blind, placebo-controlled trial. Exclusion criteria included: glaucoma, bronchial asthma, convulsive disorders, chronic pain, chronic use of analgesics, or a history of alcohol or opioid dependency. Surgeons were blinded to suppository placement which was administered after induction of anesthesia. All patients underwent a standardized anesthesia regimen. Postoperative pain was assessed by a visual analog scale (VAS) and postoperative narcotic use was calculated in intravenous morphine equivalents. RESULTS: Ninety-nine patients were included in the analysis. The B & O and control groups were not significantly different in terms of age, body mass index, operative time, nerve sparing status or prostatic volume. Postoperative pain was significantly improved during the first two postoperative hours in the B & O group. Similarly, 24-hour morphine consumption was significantly lower in patients who received a B & O. No adverse effects secondary to suppository placement were identified. CONCLUSION: Preoperative administration of B & O suppository results in significantly decreased postoperative pain and 24-hour morphine consumption in patients undergoing RALP.


Subject(s)
Analgesics, Opioid/administration & dosage , Atropa belladonna , Morphine/administration & dosage , Muscarinic Antagonists/administration & dosage , Pain, Postoperative/drug therapy , Phytotherapy , Plant Preparations/administration & dosage , Preoperative Care/methods , Prostatectomy/adverse effects , Aged , Analgesia, Patient-Controlled , Analgesics, Opioid/therapeutic use , Atropine/administration & dosage , Atropine/therapeutic use , Double-Blind Method , Humans , Laparoscopy , Male , Middle Aged , Muscarinic Antagonists/therapeutic use , Pain, Postoperative/economics , Phytotherapy/economics , Plant Preparations/therapeutic use , Preoperative Care/economics , Prostatic Neoplasms/surgery , Robotics , Scopolamine/administration & dosage , Scopolamine/therapeutic use , Suppositories
20.
J Med Food ; 13(3): 584-8, 2010 Jun.
Article in English | MEDLINE | ID: mdl-20521984

ABSTRACT

This study was carried out to examine the effects of ethanol extract (EXPG) and saponin (SAP) from Platycodon grandiflorum on scopolamine-induced amnesia in mice. Fifty male ICR mice were assigned to five groups--normal (normal diet + saline), control (normal diet + scopolamine), EXPG 0.2% (normal diet + 0.2% EXPG + scopolamine), EXPG 0.5% (normal diet + 0.5% EXPG + scopolamine), and SAP 0.02% (normal diet + 0.02% SAP + scopolamine)--and fed each diet ad libitum. After 4 weeks of feeding the appropriate diet, scopolamine (1 mg/kg, i.p.) was given to mice 45 minutes before the passive avoidance and Morris water maze tasks. Both the EXPG groups and the SAP group exhibited significant amelioration of scopolamine-induced amnesia as measured in both the passive avoidance task and the Morris water maze task. Moreover, acetylcholinesterase (AChE) activity and the levels of thiobarbituric acid-reactive substance (TBARS) in the serum and brain of the EXPG groups were lower than those of the control group. These results suggest that EXPG may improve the cognitive deficit caused by scopolamine and that these effects might be due to EXPG mediated by inhibition of AChE activity and inhibition of TBARS.


Subject(s)
Amnesia/drug therapy , Plant Extracts/administration & dosage , Platycodon/chemistry , Saponins/administration & dosage , Scopolamine/adverse effects , Amnesia/chemically induced , Amnesia/psychology , Animals , Disease Models, Animal , Ethanol/chemistry , Humans , Male , Maze Learning , Mice , Mice, Inbred ICR , Scopolamine/administration & dosage
SELECTION OF CITATIONS
SEARCH DETAIL